Skip to content

Acupuncture Treatment for Chronic Sciatica: the Neuroimaging Pain-network Study

Acupuncture Treatment on Chronic Sciatica: the Efficacy, Mechanism, and Functional Neuroimaging Pain-network Study

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03489681
Enrollment
80
Registered
2018-04-05
Start date
2018-08-01
Completion date
2020-01-31
Last updated
2019-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MRI, Functional, Therapy, Acupuncture

Keywords

acupuncture, sciatica, default mode network

Brief summary

Sciatica is a common pain disorder in the neurological clinic that typically present as low back or gluteal pain and may radiate to one leg with motor or sensory complaint. Sciatica has drawn more attention worldwide as a public health issue for its pain disability, high prevalence and significant medical and economic burden. A meta-analysis of sciatica treatment revealed discectomy, epidural injections, non-opioid analgesics, and acupuncture might relieve pain. However, the central effect of acupuncture-induced analgesia and its functional connectivities in various brain region remain unclear. Besides, the number of acupoints selection and its correlation in functional connectivity also need to be discussed. This clinical trial would collect the sciatica subjects assign by intent to treat, divided to acupuncture and non-acupuncture herbal control group. The treatment of acupuncture assigns randomized as high dose and low dose acupuncture group. The acupuncture will perform two times a week for four weeks. The primary outcomes are visual analog scale for pain and sciatica bothersomeness index; the secondary outcomes are Roland's disability questionnaire for sciatica, WHOQOL, and traditional Chinese medical constitutional scale. The functional magnetic resonance imaging scan would apply at the baseline and after four weeks' treatment. This study aims to explore the model of DMN in sciatica patients; it's central effect in different stimulation modality and to investigate the mechanism of the long-lasting, sustained impact in different acupuncture dosage.

Interventions

DEVICEacupuncture

Low dose group: Twenty patients will assign for low dose group treatment; as six acupoints as Shensu (BL 54), Huantiao (GB 30), Weizhong (BL 40), Yanglingquan (GB 34), Kunlun (BL 60), Juegu (GB 39). High dose group: Twenty patients will assign for high dose group treatment. These acupoints contains of eighteen acupoints, as Shenshu (BL 54), Dachangshu (BL 25) , Xiaochangshu (BL 27), Huantiao (GB 30), Yinmen (BL 37) , Zhibien (BL 54), Chengfu (BL 36), Fengshi (GB 31), Weizhong (BL 40), Zusanli (ST 36) Yanglingquan (GB 34), Yinlingquan (SP 9), Feiyang (BL 58), Sanyinjiao (SP 6), Juegu (GB 39), KunLun (BL 60), , Taixi (KI 3), Shenmai (BL 62).

Sponsors

Lotung Poh-Ai Hospital
CollaboratorOTHER
Taipei Veterans General Hospital, Taiwan
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

The investigators performed a prospective, randomized controlled study with three arms, the high-dose acupuncture, low-dose acupuncture, and healthy controlled groups.

Eligibility

Sex/Gender
ALL
Age
35 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

1. 35 - 70 y/o. 2. Low back or gluteal pain radiating into one leg. 3. Pain duration of at least two weeks.

Exclusion criteria

1. Known or suspected severe spinal pathology (for example, cauda equina syndrome, or spinal fracture). 2. Pregnant or breastfeeding women. 3. Scheduled or being considered for spinal surgery or interventional procedures for sciatica during the 8-week treatment period. 4. Administration of sedative or analgesics within 24 h before the fMRI scan. 5. Comorbidities include systemic malignancy, bleeding tendency, rheumatic arthritis and other known autoimmune diseases. 6. Focal neurologic deficits with progressive or disabling symptoms 7. History of received acupuncture treatment in the past one month. 8. Any contraindication related to acupuncture and MRI. 9. Visual analog scale \< 3. 10. Low back pain without sciatica.

Design outcomes

Primary

MeasureTime frameDescription
Visual Analog Scale (VAS)Change from Baseline VAS at 4 weekspain scale; from 0 to 10; score 0: no pain, score 10: unbearable pain, the higher values represent, the worse outcome

Secondary

MeasureTime frameDescription
Sciatica Bothersome Index (SBI)Change from Baseline SBI at 4 weeksscore 0: not bothersome; score 24: extremely bothersome, the higher values represent, the worse outcome
Roland Disability Questionnaire for Sciatica (RDQS)Change from Baseline RDQS at 4 weeksEvaluation of Disability of sciatica; score 0: not the disability, score 24: most disability; the higher values represent, the worse outcome
The World Health Organization Quality of Life -brief edition (WHOQOL-Brief)Change from Baseline WHOQOL-Brief at 4 weeksevaluation of daily life quality; the more the scores, the better the quality of life subscale: 1 Physical health (score 4-20); 2 Psychological (score 4-20); 3 Social relationships(score 4-20); 4 Environment (score 4- 20), total score: minimum 8, maximum 80); the higher values represent, the better outcome
Body Constitution Questionnaire (BCQ)baseline (1st time rsMRI examination)Traditional Chinese medicine (TCM), is an ancient system of personalized medicine based on body constitution (BC) theory. BC is the fundamental physiological component of a person, and different BC types are variously susceptible to disease and affect the development and prognosis of diseases. Patient classification is important in TCM, Body Constitution Questionnaire (BCQ) is developed by Prof. Su (Taiwan,2009); which classified people with their personalized trait 'body constitution' and scoring as 'Yin- deficiency', Yang-deficiency' and 'Phlegm & dampness'. The more the scores, the more tendency of the BCQ sub-type( cut off point, 30 points, 31 points, and 27 points respectively).

Countries

Taiwan

Contacts

Primary ContactFang-Pey, Chen, MD
fpchen@vghtpe.gov.tw886-2-28757452

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 20, 2026